Section Arrow
ELDN.NASDAQ
- Eledon Pharmaceuticals
Quotes are at least 15-min delayed:2025/11/07 14:57 EST
Regular Hours
Last
 2
-2.1 (-51.22%)
Day High 
2.15 
Prev. Close
4.1 
1-M High
4.6 
Volume 
22.91M 
Bid
1.99
Ask
2
Day Low
1.43 
Open
1-M Low
2.5794 
Market Cap 
245.52M 
Currency USD 
P/E 6.32 
%Yield -- 
10-SMA 4.09 
20-SMA 3.58 
50-SMA
52-W High 5.0826 
52-W Low 2.315 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.65/-1.31
Enterprise Value
246.16M
Balance Sheet
Book Value Per Share
0.84
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals4.51-0.11-2.38%-- 
ELDNEledon Pharmaceuticals2.0606-2.0394-49.74%6.32PE
IOVAIovance Biotherapeutics2.37+0.06+2.60%-- 
NTLAIntellia Therapeutics9.39-2.93-23.78%-- 
MTVAMetaVia Inc0.8938+0.0438+5.15%-- 
Quotes are at least 15-min delayed:2025/11/07 14:57 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.